Subcutaneous alemtuzumab for Sézary Syndrome in the very elderly

Revised Response Criteria for Malignant Lymphoma

Bruce D. Cheson, Beate Pfistner, Malik E. Juweid et al. · Journal of Clinical Oncology · 2007 · 4.4K citations · Full text

Medicine, Oncology, Pathology +15

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

Madeleine Duvic, Rakshandra Talpur, Xiao Ni et al. · Blood · 2006 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +13

Bexarotene Is Effective and Safe for Treatment of Refractory Advanced-Stage Cutaneous T-Cell Lymphoma: Multinational Phase II-III Trial Results

Madeleine Duvic, Kenneth B. Hymes, Peter Heald et al. · Journal of Clinical Oncology · 2001 · 704 citations

Medicine, Oncology, Pharmacology +14

Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome

Jeanette Lundin, Hans Hagberg, Roland Repp et al. · Blood · 2003 · 389 citations · Full text

Life Sciences, Immunology, Oncology +9

Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration

G Hale, Peppy Rebello, Lee Brettman et al. · Blood · 2004 · 182 citations · Full text

Pharmacy, Immunology, Oncology +14